SEC Form 4 · accession 0001209191-19-016822
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 5:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2019 | M | 10,763 | $3.19 | A | 678,844 | D | |
| Common Stock | Mar 1, 2019 | M | 8,770 | $3.82 | A | 687,614 | D | |
| Common Stock | Mar 1, 2019 | M | 467 | $6.45 | A | 688,081 | D | |
| Common StockF2 | Mar 1, 2019 | S | 4,618 | $12.9706 | D | 683,463 | D | |
| Common StockF3 | Mar 1, 2019 | S | 15,382 | $13.7876 | D | 668,081 | D | |
| Common Stock | holding | — | — | — | 64,895 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F4 | $3.19 | Mar 1, 2019 | M | 10,763 | D | — | Jan 3, 2024 | Common Stock | 10,763 | 10,209 | D |
| Stock Options (right to buy)F4 | $3.82 | Mar 1, 2019 | M | 8,770 | D | — | Jun 26, 2024 | Common Stock | 8,770 | 0 | D |
| Stock Options (right to buy)F4 | $6.45 | Mar 1, 2019 | M | 467 | D | — | Feb 15, 2022 | Common Stock | 467 | 0 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018.
- F2This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $13.31. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.38 to $13.99. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4All of the options were fully vested and exercisable as of March 1, 2019
Remarks
The options exercised in the transaction represent approximately 1.08% of Mr. Crowley's ownership at the time of the transaction. Mr. Crowley intends to exercise his options on a monthly basis.